Cargando…

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration

Patients with non-valvular atrial fibrillation (NVAF) exhibit a high risk of stroke, which is associated with high mortality. Thus, stroke prevention is crucial for the overall management of NVAF. Two categories of drugs, vitamin K antagonist warfarin and non-vitamin K antagonist oral anticoagulants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Shujuan, Hong, Xuejiao, Cao, Jingjing, Cai, Haixia, Du, Song, Ma, Peizhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468491/ https://www.ncbi.nlm.nih.gov/pubmed/32973522 http://dx.doi.org/10.3389/fphar.2020.01293

Ejemplares similares

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
por: Kim, Hyue Mee, et al.
Publicado: (2019)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2014)

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
por: Cases, Aleix, et al.
Publicado: (2021)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
por: Oh, Seil, et al.
Publicado: (2018)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea
por: Han, Seongwook, et al.
Publicado: (2021)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients
por: Mincu, Raluca Ileana, et al.
Publicado: (2019)

Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea
por: Bae, Hee-Joon, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Special considerations for therapeutic choice of non–vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
por: Okumura, Ken, et al.
Publicado: (2016)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso
por: Yameogo, Aristide Relwendé, et al.
Publicado: (2016)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls
por: Shanah, Layla, et al.
Publicado: (2020)

Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation
por: Song, Ting, et al.
Publicado: (2021)

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care
por: Guimarães, Patrícia O, et al.
Publicado: (2015)

Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Kwon, Soonil, et al.
Publicado: (2021)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Non‐Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non‐Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis
por: Sitticharoenchai, Patita, et al.
Publicado: (2021)

Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non‐valvular atrial fibrillation (cognitive decline and dementia in patients with non‐valvular atrial fibrillation [CAF] trial)
por: Bunch, Thomas Jared, et al.
Publicado: (2022)

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
por: Pan, Kuo‐Li, et al.
Publicado: (2017)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lidtj6jmcutmi5epinlioug9jr